- Report
- January 2026
- 196 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 193 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2025
- 180 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2025
- 150 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- July 2025
- 85 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- November 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- November 2025
- 400 Pages
Global
From €3499EUR$3,995USD£3,037GBP
- Report
- June 2025
- 100 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- December 2025
- 200 Pages
Global
From €2619EUR$2,990USD£2,273GBP
- Report
- May 2025
- 200 Pages
Global
From €2181EUR$2,490USD£1,893GBP
- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 183 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP

The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more